BioSpace News Archive

Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies Virtual Healthcare Conference on Tuesday, June 2, at 8:30 a.m. EDT.

RAPT Therapeutics, Inc. announced that Brian Wong, M.D., Ph.D., President and CEO, will present a corporate update and company overview at the Jefferies 2020 Healthcare Conference on Tuesday, June 2nd at 9:30 a.m. Eastern Time.

Principia Biopharma Inc. announced upcoming presentations at the European Hematology Association and the International Society on Thrombosis and Haemostasis congresses from Principia’s clinical program evaluating rilzabrutinib in patients with immune thrombocytopenia, a rare autoimmune disease that causes high risk for bleeding, excessive bruising, fatigue and potential for life threatening intracranial bleeding due to destruction of platelets.

Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 2-4, 2020.

AnPac Bio-Medical Science Co., Ltd. announced that another new US patent titled “Apparatus for Improved Disease Detection” was granted to the Company by the United States Patent and Trademark Office on May 20, 2020, which is the second AnPac Bio patent granted this month, and the third in 2020.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) (“Teva”), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.

Zynerba Pharmaceuticals, Inc., the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters on the safety, efficacy and quality of life results of the Phase 2 BELIEVE Administered as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy) clinical trial.

Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, announced that Dr. Mark Sirgo, Chief Executive Officer, will be presenting at the Jefferies 2020 Healthcare Conference on Wednesday, June 3rd at 1:00 PM Eastern Time.

May 26, 2020 10:49 UTC New Collaboration to Leverage Complementary Expertise and Capabilities with rVSV Technology to Advance Novel Vaccine Candidate KENILWORTH, N.J. & NEW YORK--( BUSINESS WIRE )-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, today announced a new collaboration to develop an investigational vaccine against SARS

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, provided an update on the progress it is making with its partner, Teledyne Scientific & Imaging, in further validating the power of Resonant’s Infinite Synthesized Networks (ISN ® ) software platform by developing wide bandwidth, high frequency XBAR ® filters with its fou